Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Pridinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.80 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.80 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.67 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.67 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.67 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.67 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.53 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.53 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pridinol SCHEMBL10786634 | 0.93 | CYP2D6 (0.87) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Pridinol SCHEMBL143298 | 0.89 | CHRM2 (1.00) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Pridinol SCHEMBL27496509 | 0.88 | CHRM2 (0.97) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Pridinol SCHEMBL363996 | 0.88 | CHRM2 (0.97) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Pridinol SCHEMBL29250415 | 0.88 | CHRM2 (0.97) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| SCHEMBL5497586 | 0.82 | CYP2D6 (0.85) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL5501561 | 0.81 | CHRM2 (0.82) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Diphenidol SCHEMBL34469 | 0.80 | CHRM3 (1.00) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| Diphenidol SCHEMBL195192 | 0.79 | CHRM3 (1.00) | CYP2D6MAPK1CHRM2CHRM1KCNH2 | |
| SCHEMBL10307554 | 0.79 | CHRM3 (0.97) | CYP2D6MAPK1CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION | 2022-05-19 | — | — | US | claimed |
| EP-3923920-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | The Ketamine Research Foundation (US) | 2021-12-22 | — | — | EP | claimed |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2021-04-22 | — | — | US | claimed |
| WO-2021026232-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION (US) | 2021-02-11 | — | — | WO | claimed |
| EP-3548014-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | Wolfson, Philip, E. (US) | 2019-10-09 | — | — | EP | claimed |
| EP-2001450-B1 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RES PRIVATE LIMITED (IN) | 2019-01-30 | — | — | EP | claimed |
| WO-2018102488-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2018-06-07 | — | — | WO | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20150352040-A1 | TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY | AFGIN PHARMA, LLC | 2015-12-10 | — | — | US | claimed |
| US-20070065463-A1 | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions | AFGIN PHARMA LLC | 2007-03-22 | — | — | US | claimed |
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| EP-1644004-A2 | TROPICAL THERAPY FOR THE TREATMENT OF MIGRAINES, MUSCLE SPRAINS, MUSCLE SPASM, SPASTICITY AND RELATED CONDITIONS | Aung-din, Ronald (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2004112723-A2 | TROPICAL THERAPY FOR THE TREATMENT OF MIGRAINES, MUSCLE SPRAINS, MUSCLE SPASM, SPASTICITY AND RELATED CONDITIONS | AUNG-DIN RONALD (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | OXTR, PNISR, KCNQ5 | CHRM1 1087/4885HTR1A 166/4885DRD2 128/4885 |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | CHRM1 2865/4885HTR1A 2059/4885DRD2 4518/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | CHRM1 2865/4885HTR1A 2059/4885DRD2 4518/4885 |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | KCNK5, KCNQ5, KCND2 | CHRM1 1091/4885HTR1A 99/4885DRD2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.